Neurokinin-1 receptor antagonists: review of their role for the prevention of chemotherapy-induced nausea and vomiting in adults. Issue 7 (3rd July 2019)

• Record Type: Journal Article
• Authors: Karthaus, Meinolf; Schiel, Xaver; Ruhlmann, Christina H.; Celio, Luigi
• Is Part Of: Expert review of clinical pharmacology. Volume 12:Issue 7(2019)
• Page Start: 661
• Page End: 680
• Publication Date: 2019-07-03
• Subjects: Chemotherapy-induced nausea and vomiting (CINV) -- emesis -- antiemetics -- guidelines -- adherence; Clinical pharmacology -- Periodicals; 615.105
• DOI: 10.1080/17512433.2019.1621162
• Languages: English
• ISSNs: 1751-2433

Abstract

ABSTRACT: Introduction : The addition of neurokinin-1 receptor antagonists (NK1 RAs) to standard prophylaxis of 5-hydroxytryptamine-3 RA (5-HT3 RA) plus dexamethasone more effectively prevents chemotherapy-induced nausea and vomiting (CINV) associated with highly and moderately emetogenic chemotherapy. Areas covered : This review presents the evidence base for the use of oral and intravenous (IV) NK1 RAs, focusing on the pharmacologic and clinical properties as a class, and highlighting differences between agents. A PubMed literature search was conducted from 2000 to 2018. Expert opinion : Adherence to international antiemetic guidelines remains a clinical challenge. Strategies to simplify antiemetic regimens and facilitate their administration may improve compliance and treatment outcomes. The use of fixed-combination antiemetics offers clinical utility, in combining an NK1 RA with a 5-HT3 RA in a single oral dose. The use of long-lasting NK1 RAs and administering CINV prophylaxis closer to the time of chemotherapy may also assist with guideline and treatment compliance, diminishing the need for home-based administration, and potentially reducing resource utilization. The availability of IV and oral formulations of NK1 RAs and NK1 RA–5-HT3 RA fixed combinations offers further utility, particularly for those patients unsuited for oral administration. However, safety considerations with respect to injection site toxicity and hypersensitivity reactions of the new NK1 RA IV formulations deserve close attention.